Comparisons of in vitro drug resistance between samples from different FAB subtypes of children with newly diagnosed AML
Drug . | LC50 values . | FAB M1/M2 . | FAB M4 . | FAB M5 . | RR4-150 M4-M1/2 . | RR4-151M1/2-M5 . | RR‡ M4-M5 . |
---|---|---|---|---|---|---|---|
Cytarabine | Median | 0.51 | 0.43 | 0.15 | 0.8 | 3.44-153 | 2.94-153 |
P25-P75 | 0.33-1.64 | 0.30-0.63 | 0.12-0.44 | ||||
n | 42 | 37 | 22 | ||||
Daunorubicin | Median | 0.14 | 0.35 | 0.11 | 2.54-153 | 1.3 | 3.24-155 |
P25-P75 | 0.09-0.35 | 0.25-0.45 | 0.05-0.22 | ||||
n | 40 | 37 | 20 | ||||
Idarubicin | Median | 0.13 | 0.26 | 0.10 | 2.0 | 1.3 | 2.64-155 |
P25-P75 | 0.09-0.27 | 0.16-0.31 | 0.03-0.13 | ||||
n | 26 | 26 | 12 | ||||
Doxorubicin | Median | 0.49 | 0.81 | 0.27 | 1.7 | 1.8 | 3.04-153 |
P25-P75 | 0.36-0.81 | 0.52-1.02 | 0.11-0.43 | ||||
n | 31 | 27 | 16 | ||||
Aclarubicin | Median | 0.17 | 0.28 | 0.33 | 1.6 | NC | NC |
P25-P75 | 0.10-0.38 | 0.28-0.46 | 0.03-0.914-154 | ||||
n | 11 | 5 | 3 | ||||
Mitoxantrone | Median | 0.08 | 0.25 | 0.02 | 3.1 | 4.0 | 12.54-153 |
P25-P75 | 0.02-0.19 | 0.05-0.50 | 0.00-0.11 | ||||
n | 35 | 38 | 14 | ||||
Etoposide | Median | 7.36 | 11.96 | 1.37 | 1.6 | 5.44-155 | 8.74-155 |
P25-P75 | 2.62-27.85 | 6.73-24.78 | 0.54-3.02 | ||||
n | 40 | 37 | 23 | ||||
6-Mercaptopurine | Median | 55.6 | 93.8 | 134.6 | 1.7 | NC | NC |
P25-P75 | 47.6-103.0 | 70.8->500 | 15.0-145.84-154 | ||||
n | 8 | 5 | 3 | ||||
6-Thioguanine | Median | 5.20 | 8.98 | 6.18 | 1.7 | 0.8 | 1.5 |
P25-P75 | 3.34-9.69 | 5.57-12.64 | 3.50-9.08 | ||||
n | 43 | 36 | 22 | ||||
Amsacrine | Median | 0.24 | 0.94 | 0.15 | 3.9 | 1.6 | 6.34-155 |
P25-P75 | 0.13-1.00 | 0.53-1.47 | 0.08-0.36 | ||||
n | 28 | 35 | 14 | ||||
Ifosfamide | Median | 11.60 | 12.95 | 11.76 | 1.1 | 1.0 | 1.1 |
P25-P75 | 5.93-13.76 | 11.37-15.04 | 4.86-13.89 | ||||
n | 28 | 34 | 19 | ||||
Thiotepa | Median | 4.00 | 8.51 | 0.70 | 2.1 | NC | NC |
P25-P75 | 1.87-8.27 | 7.08-12.00 | 0.51-8.444-154 | ||||
n | 9 | 9 | 3 | ||||
Busulfan | Median | 33.33 | 38.49 | 25.60 | 1.2 | 1.3 | 1.5 |
P25-P75 | 25.59-67.58 | 27.93-51.19 | 9.72-58.21 | ||||
n | 29 | 34 | 13 | ||||
Cisplatin | Median | 3.79 | 7.03 | 2.30 | 1.9 | 1.6 | 3.1 |
P25-P75 | 2.86-8.53 | 5.37-9.42 | 1.41-6.254-154 | ||||
n | 7 | 7 | 4 | ||||
L-Asparaginase# | Median | 0.63 | 1.09 | 0.30 | 1.7 | 2.1 | 3.64-153 |
P25-P75 | 0.18-1.58 | 0.65-1.59 | 0.01-1.18 | ||||
n | 31 | 36 | 17 | ||||
Vincristine | Median | 2.99 | 21.55 | 0.53 | 7.2 | 5.6 | 40.74-160 |
P25-P75 | 1.81-18.02 | 2.64-35.94 | 0.18-23.96 | ||||
n | 43 | 37 | 20 | ||||
Vindesine | Median | 3.14 | 17.66 | ND | 5.6 | NC | NC |
P25-P75 | 2.04-20.02 | 14.85-36.77 | 0.68-8.754-154 | ||||
n | 6 | 5 | 2 | ||||
Prednisolone | Median | >250 | >250 | >250 | NC | NC | NC |
P25-P75 | 213.5->250 | >250->250 | >250->250 | ||||
n | 43 | 39 | 24 | ||||
Dexamethasone | Median | >6 | >6 | >6 | NC | NC | NC |
P25-P75 | >6->6 | >6->6 | >6->64-154 | ||||
n | 8 | 5 | 3 |
Drug . | LC50 values . | FAB M1/M2 . | FAB M4 . | FAB M5 . | RR4-150 M4-M1/2 . | RR4-151M1/2-M5 . | RR‡ M4-M5 . |
---|---|---|---|---|---|---|---|
Cytarabine | Median | 0.51 | 0.43 | 0.15 | 0.8 | 3.44-153 | 2.94-153 |
P25-P75 | 0.33-1.64 | 0.30-0.63 | 0.12-0.44 | ||||
n | 42 | 37 | 22 | ||||
Daunorubicin | Median | 0.14 | 0.35 | 0.11 | 2.54-153 | 1.3 | 3.24-155 |
P25-P75 | 0.09-0.35 | 0.25-0.45 | 0.05-0.22 | ||||
n | 40 | 37 | 20 | ||||
Idarubicin | Median | 0.13 | 0.26 | 0.10 | 2.0 | 1.3 | 2.64-155 |
P25-P75 | 0.09-0.27 | 0.16-0.31 | 0.03-0.13 | ||||
n | 26 | 26 | 12 | ||||
Doxorubicin | Median | 0.49 | 0.81 | 0.27 | 1.7 | 1.8 | 3.04-153 |
P25-P75 | 0.36-0.81 | 0.52-1.02 | 0.11-0.43 | ||||
n | 31 | 27 | 16 | ||||
Aclarubicin | Median | 0.17 | 0.28 | 0.33 | 1.6 | NC | NC |
P25-P75 | 0.10-0.38 | 0.28-0.46 | 0.03-0.914-154 | ||||
n | 11 | 5 | 3 | ||||
Mitoxantrone | Median | 0.08 | 0.25 | 0.02 | 3.1 | 4.0 | 12.54-153 |
P25-P75 | 0.02-0.19 | 0.05-0.50 | 0.00-0.11 | ||||
n | 35 | 38 | 14 | ||||
Etoposide | Median | 7.36 | 11.96 | 1.37 | 1.6 | 5.44-155 | 8.74-155 |
P25-P75 | 2.62-27.85 | 6.73-24.78 | 0.54-3.02 | ||||
n | 40 | 37 | 23 | ||||
6-Mercaptopurine | Median | 55.6 | 93.8 | 134.6 | 1.7 | NC | NC |
P25-P75 | 47.6-103.0 | 70.8->500 | 15.0-145.84-154 | ||||
n | 8 | 5 | 3 | ||||
6-Thioguanine | Median | 5.20 | 8.98 | 6.18 | 1.7 | 0.8 | 1.5 |
P25-P75 | 3.34-9.69 | 5.57-12.64 | 3.50-9.08 | ||||
n | 43 | 36 | 22 | ||||
Amsacrine | Median | 0.24 | 0.94 | 0.15 | 3.9 | 1.6 | 6.34-155 |
P25-P75 | 0.13-1.00 | 0.53-1.47 | 0.08-0.36 | ||||
n | 28 | 35 | 14 | ||||
Ifosfamide | Median | 11.60 | 12.95 | 11.76 | 1.1 | 1.0 | 1.1 |
P25-P75 | 5.93-13.76 | 11.37-15.04 | 4.86-13.89 | ||||
n | 28 | 34 | 19 | ||||
Thiotepa | Median | 4.00 | 8.51 | 0.70 | 2.1 | NC | NC |
P25-P75 | 1.87-8.27 | 7.08-12.00 | 0.51-8.444-154 | ||||
n | 9 | 9 | 3 | ||||
Busulfan | Median | 33.33 | 38.49 | 25.60 | 1.2 | 1.3 | 1.5 |
P25-P75 | 25.59-67.58 | 27.93-51.19 | 9.72-58.21 | ||||
n | 29 | 34 | 13 | ||||
Cisplatin | Median | 3.79 | 7.03 | 2.30 | 1.9 | 1.6 | 3.1 |
P25-P75 | 2.86-8.53 | 5.37-9.42 | 1.41-6.254-154 | ||||
n | 7 | 7 | 4 | ||||
L-Asparaginase# | Median | 0.63 | 1.09 | 0.30 | 1.7 | 2.1 | 3.64-153 |
P25-P75 | 0.18-1.58 | 0.65-1.59 | 0.01-1.18 | ||||
n | 31 | 36 | 17 | ||||
Vincristine | Median | 2.99 | 21.55 | 0.53 | 7.2 | 5.6 | 40.74-160 |
P25-P75 | 1.81-18.02 | 2.64-35.94 | 0.18-23.96 | ||||
n | 43 | 37 | 20 | ||||
Vindesine | Median | 3.14 | 17.66 | ND | 5.6 | NC | NC |
P25-P75 | 2.04-20.02 | 14.85-36.77 | 0.68-8.754-154 | ||||
n | 6 | 5 | 2 | ||||
Prednisolone | Median | >250 | >250 | >250 | NC | NC | NC |
P25-P75 | 213.5->250 | >250->250 | >250->250 | ||||
n | 43 | 39 | 24 | ||||
Dexamethasone | Median | >6 | >6 | >6 | NC | NC | NC |
P25-P75 | >6->6 | >6->6 | >6->64-154 | ||||
n | 8 | 5 | 3 |
The results are expressed in LC50 values given as μg/mL.
NC indicates that the RR could not be calculated.
RR is the median LC50 for FAB M4 divided by the median LC50 for FAB M1/M2. RR > 1.0 indicates that for the given drug, FAB M4 is more resistant than FAB M1/M2.
RR is the median LC50 for FAB M1/M2 divided by the median LC50 for FAB M5. RR > 1.0 indicates that for the given drug, FAB M1/M2 is more resistant than FAB M5.
RR is the median LC50 for FAB M4 divided by the median LC50 for FAB M5. RR > 1.0 indicates that for the given drug, FAB M4 is more resistant than FAB M5.
P > .001 and P ≤ .01, as determined by the Mann-Whitney U test.
P ≤ .001, as determined by the Mann-WhitneyU test.
The minimum to maximum range is given, rather than P25 and P75.
# l-asparaginase is given as IU/mL, not as μg/mL.
P = .016.